Nasdaq Copenhagen

Updated Financial Calendar for 2022

Retrieved on: 
Monday, May 16, 2022 - 1:50pm

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer: +45 2898 9055

Key Points: 
  • Anders Vadsholt, Chief Executive Officer and Chief Financial Officer: +45 2898 9055
    Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC).
  • Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs).
  • Arimoclomol is administered orally, and has now been studied in 10 Phase 1, four Phase 2, and three pivotal Phase 2/3 trials.
  • The company has requested a type B-meeting to be held early Q3 2022.

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

Retrieved on: 
Sunday, May 15, 2022 - 10:00pm

KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system diseases.

Key Points: 
  • KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system diseases.
  • KemPharm will pay Orphazyme a total of USD 12.8 million in cash and assume liabilities estimated to equal approximately USD 5.2 million.
  • Since Orphazyme is under in-court restructuring, the primary objective was to secure a deal that satisfies our obligations towards the creditors including our employees.
  • Following completion of the deal, Orphazyme will no longer have any ongoing operational business activities.

Ørsted and TotalEnergies partner to participate in Dutch offshore wind tenders

Retrieved on: 
Friday, May 13, 2022 - 2:14pm

Paris/Den Haag, 13 May, 2022 rsted and TotalEnergies have joined forces to jointly submit bids for the two Dutch offshore wind tenders Holland Coast West with the aim to achieve net positive impact on biodiversity and the Dutch energy system.

Key Points: 
  • Paris/Den Haag, 13 May, 2022 rsted and TotalEnergies have joined forces to jointly submit bids for the two Dutch offshore wind tenders Holland Coast West with the aim to achieve net positive impact on biodiversity and the Dutch energy system.
  • As world-class leaders in renewable energy and offshore wind, rsted and TotalEnergies will combine their strengths in these tenders with a view to contribute to the Netherlands objective of developing more than 70 GW of offshore wind capacity by 2050 for power generation associated with large scale hydrogen production.
  • As the largest offshore wind farm developer in the world, rsted has industry-leading experience in developing and constructing offshore wind farms in the most sustainable and ecologically friendly manner.
  • Rasmus Errboe, Head of Region Continental Europe at rsted, says: We are very pleased with our partnership with TotalEnergies for the upcoming Dutch tenders.

Jabra Engage 55: the portable professional headset, designed for ultimate call security and quality

Retrieved on: 
Tuesday, May 10, 2022 - 6:01pm

Engineered to enhance your communications, the latest headset comes with the highest DECT security with military-grade 256-bit encryption and noise cancelling technology.

Key Points: 
  • Engineered to enhance your communications, the latest headset comes with the highest DECT security with military-grade 256-bit encryption and noise cancelling technology.
  • The Jabra Engage 55 is a brand-new DECT wireless professional headset designed for superior conversation quality.
  • Research** also found that a person's credibility in virtual calls relies on their audio quality; the poorer the quality, the less credible we consider someone to be.
  • When we experience poor quality audio online, our brain naturally strains to figure out what is being said.

Jabra Introduces Dynamic Composition for PanaCast 50, Seamlessly Bridging Hybrid Workers in Microsoft Teams Rooms with Remote Meeting Participants

Retrieved on: 
Thursday, May 5, 2022 - 11:10pm

This software-enabled experience leverages AI to automatically provide close-up views of participants in physical meeting rooms mimicking the view of those joining from afar.

Key Points: 
  • This software-enabled experience leverages AI to automatically provide close-up views of participants in physical meeting rooms mimicking the view of those joining from afar.
  • The technology is born out of a collaboration between Jabra and Microsoft to improve virtual meeting rooms in response to hybrid workers' increased need for seamless meeting experiences, no matter where or how they are participating.
  • Dynamic Composition from Jabra ushers us into an even newer normal in which all meeting participants have an increased ability to be seen and heard."
  • The Dynamic Composition view update will be available beginning Junefor PanaCast 50 users in a Microsoft Teams Rooms environment.

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate

Retrieved on: 
Thursday, May 5, 2022 - 9:04am

COPENHAGEN, Denmark, May 5, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today additional results from its Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 vaccine candidate.

Key Points: 
  • COPENHAGEN, Denmark, May 5, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today additional results from its Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 vaccine candidate.
  • Paul Chaplin, President and CEO of Bavarian Nordic, commented: We now have demonstrated a large range of immune responses against different variants of concern, including Omicron.
  • Supported by the Danish State, Bavarian Nordic plans to initiate soon a Phase 3 program of ABNCoV2.
  • Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.

Notification of managers’ transactions

Retrieved on: 
Thursday, May 5, 2022 - 8:03am

The rsted vision is a world that runs entirely on green energy.

Key Points: 
  • The rsted vision is a world that runs entirely on green energy.
  • rsted develops, constructs, and operates offshore and onshore wind farms, solar farms, energy storage facilities, renewable hydrogen and green fuels facilities, and bioenergy plants.
  • rsted is the only energy company in the world with a science-based net-zero emissions target as validated by the Science Based Targets initiative (SBTi).
  • In 2021, the group's revenue was DKK 77.7 billion (EUR 10.4 billion).

Notification of managers' transactions

Retrieved on: 
Friday, April 29, 2022 - 8:02am

The rsted vision is a world that runs entirely on green energy.

Key Points: 
  • The rsted vision is a world that runs entirely on green energy.
  • rsted develops, constructs, and operates offshore and onshore wind farms, solar farms, energy storage facilities, renewable hydrogen and green fuels facilities, and bioenergy plants.
  • rsted is the only energy company in the world with a science-based net-zero emissions target as validated by the Science Based Targets initiative (SBTi).
  • In 2021, the group's revenue was DKK 77.7 billion (EUR 10.4 billion).

Orphazyme announces update on in-court restructuring proceedings

Retrieved on: 
Friday, April 29, 2022 - 7:46am

Copenhagen, Denmark, April 29, 2022 Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (Orphazyme or the Company), a late-stage biopharmaceutical company, announces an update to the in-court restructuring proceedings of the Company (please see company announcement no.

Key Points: 
  • Copenhagen, Denmark, April 29, 2022 Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (Orphazyme or the Company), a late-stage biopharmaceutical company, announces an update to the in-court restructuring proceedings of the Company (please see company announcement no.
  • Orphazyme has to date received certain non-binding offers (the Offers) to purchase all of Orphazymes assets and operations.
  • Following negotiations, Orphazyme, with respect to the Offers received, expects to enter into exclusive negotiations with a selected potential buyer.
  • Following completion of such transaction, Orphazyme would have no activities and would be dissolved, when possible.

Updated Financial Calendar for 2022

Retrieved on: 
Thursday, April 28, 2022 - 3:13pm

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer: +45 2898 9055

Key Points: 
  • Anders Vadsholt, Chief Executive Officer and Chief Financial Officer: +45 2898 9055
    Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC).
  • Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs).
  • Arimoclomol is administered orally, and has now been studied in 10 Phase 1, four Phase 2, and three pivotal Phase 2/3 trials.
  • The Company plans to request a Type C Meeting with the FDA in Q2 2022.